Next page: Expanded access drugs
Pipeline drugs
Several drugs are already available that will work against drug resistance. These include fostemsavir, ibalizumab and lenacapavir.
Other drugs in advanced development with also be effective.
It is good to follow this research. It can help you plan when to change ART. You might also be able to join ongoing studies to get access before a drug is approved.
The i-Base website includes updates on new drugs and new research.
This report is from 2025. The US activist group TAG produce an updated pipeline report every year.
This includes the following compounds in each class. Not all these new drugs will work against drug resistance.
NRTIs: islatravir, GS-1614 (similar to islatravir).
NNRTIs: ulonivirine (MK-8507), GS-5894.
Attachment inhibitors: fostemsavir.
Capsid inhibitors: lenacapavir, VH-499, GS-1720 (both early stage).
Fusion inhibitors: albuvirtide.
Integrase inhibitors: GS-4182, GS-6212, VH-184, VH-310 (all early stage).
Monoclonal antibodies (mAbs): ibalizumab, N6LSS, teropavimab (TAB, 3BNC117/GS 5423) and zinlirvimab (ZAB, 10-1074/GS 2872).
Last updated: 1 January 2025.